CN109153700B - 作为hiv-1抑制剂的c-3和c-17修饰的三萜类化合物 - Google Patents

作为hiv-1抑制剂的c-3和c-17修饰的三萜类化合物 Download PDF

Info

Publication number
CN109153700B
CN109153700B CN201780018790.8A CN201780018790A CN109153700B CN 109153700 B CN109153700 B CN 109153700B CN 201780018790 A CN201780018790 A CN 201780018790A CN 109153700 B CN109153700 B CN 109153700B
Authority
CN
China
Prior art keywords
ethyl
methyl
cyclohex
oxy
prop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780018790.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109153700A (zh
Inventor
陈洁
陈燕
I.B.迪克
R.A.哈特兹
N.A.米安维尔
B.诺维克-斯安斯
A.利古艾罗-伦
薛成源
N.辛
J.斯维多尔斯基
B.L.温拿布勒斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of CN109153700A publication Critical patent/CN109153700A/zh
Application granted granted Critical
Publication of CN109153700B publication Critical patent/CN109153700B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201780018790.8A 2016-02-04 2017-02-02 作为hiv-1抑制剂的c-3和c-17修饰的三萜类化合物 Active CN109153700B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291298P 2016-02-04 2016-02-04
US62/291,298 2016-02-04
PCT/IB2017/050568 WO2017134596A1 (en) 2016-02-04 2017-02-02 C-3 and c-17 modified triterpenoids as hiv-1 inhibitors

Publications (2)

Publication Number Publication Date
CN109153700A CN109153700A (zh) 2019-01-04
CN109153700B true CN109153700B (zh) 2021-03-09

Family

ID=57995251

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780018790.8A Active CN109153700B (zh) 2016-02-04 2017-02-02 作为hiv-1抑制剂的c-3和c-17修饰的三萜类化合物

Country Status (39)

Country Link
US (4) US10421774B2 (cg-RX-API-DMAC7.html)
EP (2) EP3411381B1 (cg-RX-API-DMAC7.html)
JP (1) JP6735837B2 (cg-RX-API-DMAC7.html)
KR (1) KR102795662B1 (cg-RX-API-DMAC7.html)
CN (1) CN109153700B (cg-RX-API-DMAC7.html)
AR (1) AR107512A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017215529B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018015629B1 (cg-RX-API-DMAC7.html)
CA (1) CA3013417C (cg-RX-API-DMAC7.html)
CL (1) CL2018002084A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018008157A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180387A (cg-RX-API-DMAC7.html)
CY (1) CY1124353T1 (cg-RX-API-DMAC7.html)
DK (1) DK3411381T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2018000174A (cg-RX-API-DMAC7.html)
EA (1) EA036211B1 (cg-RX-API-DMAC7.html)
ES (2) ES2957767T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210502T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054337T2 (cg-RX-API-DMAC7.html)
IL (1) IL260741B (cg-RX-API-DMAC7.html)
JO (1) JOP20170029B1 (cg-RX-API-DMAC7.html)
LT (1) LT3411381T (cg-RX-API-DMAC7.html)
MA (2) MA53358A (cg-RX-API-DMAC7.html)
MD (1) MD3411381T2 (cg-RX-API-DMAC7.html)
MX (1) MX375118B (cg-RX-API-DMAC7.html)
MY (1) MY199668A (cg-RX-API-DMAC7.html)
PE (1) PE20181355A1 (cg-RX-API-DMAC7.html)
PL (1) PL3411381T3 (cg-RX-API-DMAC7.html)
PT (1) PT3411381T (cg-RX-API-DMAC7.html)
RS (1) RS61746B1 (cg-RX-API-DMAC7.html)
RU (1) RU2716502C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201806388XA (cg-RX-API-DMAC7.html)
SI (1) SI3411381T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100210T1 (cg-RX-API-DMAC7.html)
TW (1) TWI719126B (cg-RX-API-DMAC7.html)
UA (1) UA123867C2 (cg-RX-API-DMAC7.html)
UY (1) UY37109A (cg-RX-API-DMAC7.html)
WO (1) WO2017134596A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805044B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
JP7436385B2 (ja) * 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド Hiv成熟阻害活性を有する化合物
IL293566A (en) 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
WO2025037232A1 (en) 2023-08-11 2025-02-20 ViiV Healthcare UK (No.4) Limited Tosylate salt form of a maturation inhibitor for treatment of hiv
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429607A (zh) * 2011-01-31 2013-12-04 百时美施贵宝公司 具有hiv成熟抑制活性的c-17和c-3经修饰的三萜系化合物
CN104220451A (zh) * 2012-02-15 2014-12-17 百时美施贵宝公司 具有hiv成熟抑制活性的c-3环烯三萜类化合物
CN104540844A (zh) * 2012-05-07 2015-04-22 百时美施贵宝公司 具有hiv成熟抑制活性的三萜系化合物的c-17双环胺
WO2015157483A1 (en) * 2014-04-11 2015-10-15 Bristol-Myers Squibb Company Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
CN105121454A (zh) * 2013-02-06 2015-12-02 百时美施贵宝公司 具有hiv成熟抑制活性的c-19经修饰的三萜类化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
GB0301227D0 (en) 2003-01-20 2003-02-19 Keen Group Ltd Seating apparatus
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
EP1730163A4 (en) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規17βルパン誘導体
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2956034B1 (fr) 2010-02-09 2012-02-10 Thales Sa Dispositif d'entrainement pour des joueurs de rugby
BR112012030810A2 (pt) 2010-06-04 2019-09-24 Bristol-Myers Squibb Company "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
CA2801487C (en) 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
DE102010017786A1 (de) 2010-07-07 2012-01-12 Continental Reifen Deutschland Gmbh Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung
HRP20151212T1 (hr) 2011-01-31 2015-12-04 Bristol-Myers Squibb Company C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
CN104271550B (zh) * 2011-12-14 2016-09-07 葛兰素史克有限责任公司 白桦脂醇的丙烯酸酯衍生物
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9378035B2 (en) 2012-12-28 2016-06-28 Commvault Systems, Inc. Systems and methods for repurposing virtual machines
BR112015019590A2 (pt) * 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
CN104877015B (zh) * 2014-02-28 2019-02-01 中国人民解放军军事医学科学院毒物药物研究所 一种三萜-多肽缀合物、其药物组合物及用途
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
SG11201806429PA (en) 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429607A (zh) * 2011-01-31 2013-12-04 百时美施贵宝公司 具有hiv成熟抑制活性的c-17和c-3经修饰的三萜系化合物
CN104220451A (zh) * 2012-02-15 2014-12-17 百时美施贵宝公司 具有hiv成熟抑制活性的c-3环烯三萜类化合物
CN104540844A (zh) * 2012-05-07 2015-04-22 百时美施贵宝公司 具有hiv成熟抑制活性的三萜系化合物的c-17双环胺
CN105121454A (zh) * 2013-02-06 2015-12-02 百时美施贵宝公司 具有hiv成熟抑制活性的c-19经修饰的三萜类化合物
WO2015157483A1 (en) * 2014-04-11 2015-10-15 Bristol-Myers Squibb Company Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent

Also Published As

Publication number Publication date
AU2017215529A8 (en) 2018-08-30
UA123867C2 (uk) 2021-06-16
CR20180387A (es) 2018-09-20
UY37109A (es) 2017-09-29
SI3411381T1 (sl) 2021-04-30
MA53358A (fr) 2021-07-21
CL2018002084A1 (es) 2018-09-21
SG11201806388XA (en) 2018-08-30
TWI719126B (zh) 2021-02-21
US11084845B2 (en) 2021-08-10
RU2018130181A3 (cg-RX-API-DMAC7.html) 2020-03-05
MX2018009514A (es) 2018-09-05
MD3411381T2 (ro) 2021-07-31
TW201739757A (zh) 2017-11-16
DOP2018000174A (es) 2018-10-31
EP3831839A2 (en) 2021-06-09
AU2017215529A1 (en) 2018-08-23
HUE054337T2 (hu) 2021-08-30
CO2018008157A2 (es) 2018-08-21
EA036211B1 (ru) 2020-10-14
DK3411381T3 (da) 2021-04-06
RU2018130181A (ru) 2020-03-05
MX375118B (es) 2025-03-06
US20190031709A1 (en) 2019-01-31
HRP20210502T1 (hr) 2021-05-14
PE20181355A1 (es) 2018-08-22
US20190359647A1 (en) 2019-11-28
KR20180105229A (ko) 2018-09-27
CN109153700A (zh) 2019-01-04
US20210323997A1 (en) 2021-10-21
PL3411381T3 (pl) 2021-09-13
EP3411381A1 (en) 2018-12-12
EP3831839A3 (en) 2021-07-21
ES2957767T3 (es) 2024-01-25
HK1256866A1 (en) 2019-10-04
JP2019504104A (ja) 2019-02-14
AR107512A1 (es) 2018-05-09
MA43960A (fr) 2018-12-12
US10421774B2 (en) 2019-09-24
BR112018015629B1 (pt) 2023-10-24
LT3411381T (lt) 2021-04-26
ES2862325T3 (es) 2021-10-07
BR112018015629A2 (pt) 2018-12-26
JP6735837B2 (ja) 2020-08-05
MY199668A (en) 2023-11-15
ZA201805044B (en) 2020-08-26
JOP20170029B1 (ar) 2021-08-17
EP3831839B1 (en) 2023-07-26
MA43960B1 (fr) 2021-02-26
CA3013417A1 (en) 2017-08-10
EP3411381B1 (en) 2021-01-20
IL260741B (en) 2020-04-30
US20230295220A1 (en) 2023-09-21
NZ744545A (en) 2025-03-28
WO2017134596A1 (en) 2017-08-10
RU2716502C2 (ru) 2020-03-12
PT3411381T (pt) 2021-03-18
CY1124353T1 (el) 2022-07-22
KR102795662B1 (ko) 2025-04-14
AU2017215529B2 (en) 2019-01-31
SMT202100210T1 (it) 2021-05-07
CA3013417C (en) 2024-01-02
RS61746B1 (sr) 2021-05-31
EA201891649A1 (ru) 2019-02-28

Similar Documents

Publication Publication Date Title
US11084845B2 (en) C-3 and C-17 modified triterpenoids as HIV-1 inhibitors
EP2847208B1 (en) C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity
US10780102B2 (en) Triterpenoids with HIV maturation inhibitory activity
US9969767B2 (en) Oxolupene derivatives
HK40053429A (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
HK1256866B (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
US9914747B2 (en) Extended betulinic acid analogs
HK40041853A (en) Triterpenoids with hiv maturation inhibitory activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant